Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Limited Access Phase II Trial of Pemetrexed (Alimta, LY231514) (NSC 698037) in Combination With Cisplatin (NSC 119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix.

Next Previous
Search
Trial Profile

A Limited Access Phase II Trial of Pemetrexed (Alimta, LY231514) (NSC 698037) in Combination With Cisplatin (NSC 119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jan 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pemetrexed (Primary) ; Cisplatin
  • Indications Cervical cancer
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 21 Nov 2014 Status changed from recruiting to discontinued, according to M.D. Anderson Cancer Center record.
    • 09 Jun 2010 Status changed from suspended to recruiting as reported by ClinicalTrials.gov.
    • 28 Aug 2009 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top